Suppr超能文献

内镜下黏膜切除术治疗早期食管癌的评估

Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma.

作者信息

Noguchi H, Naomoto Y, Kondo H, Haisa M, Yamatsuji T, Shigemitsu K, Aoki H, Isozaki H, Tanaka N

机构信息

The First Department of Surgery, Okayama University Medical School, Japan.

出版信息

Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):343-50.

Abstract

Esophageal superficial carcinoma safely can be resected surgically or endoscopically. We evaluated indications for endoscopic mucosal resection (EMR) and optimal treatment modality for superficial carcinoma of the esophagus based on clinical and pathologic analyses. Between January 1, 1984, and September 30, 1999, 113 patients with superficial cancer of the esophagus underwent surgical or endoscopic resection (n = 33 patients, 36 lesions). The two-channel method, esophageal EMR-tube method or EMR cap-fitted panendoscope was used. Mucosal and submucosal cancers were classified to be epithelial layer (m1), proper mucosal layer (m2), muscularis mucosae (m3), upper third of the submucosal level (sm1), middle third of the submucosal layer (sm2), or the lower third of the submucosal level (sm3) cancers, according to criteria of the Japanese Society for Esophageal Disease. Absolute indication for EMR was restricted to m1 or m2 cancers, and relative indications for EMR included m3 or sm1 lesions. In our department, indications for EMR were not related to size or circumference of lesions. Lymph vessel invasion and lymph node metastasis markedly increased in lesions that infiltrated the lamina muscularis mucosa (m3). All lesions resected with use of EMR were 0-II (flat), and the depth of invasion in 10 0-IIa or 0-IIb lesions was m1 or m2. Twenty-one 0-IIc lesions were distributed widely from m1 to sm1. All 0-IIa+IIc lesions were m3 or sm1. Preoperative diagnosis accurately was established preoperatively in 61% of patients. Complications related to EMR were detected in 21% of patients and included perforation, stenosis, and hemorrhage. Ten patients also received radiotherapy, chemotherapy, or esophagectomy with lymph node dissection after use of EMR. No such combination therapy was administered in six patients with m3 lesions, but without lymph vessel invasion. All patients treated with use of EMR, including patients with m3 cancer who did not receive additional treatment, are living without recurrence. Local resection with use of EMR could be regarded to be the preferred treatment of superficial esophageal cancers limited to the lamina propria mucosae. Endoscopic mucosal resection also could be regarded to be the preferred treatment of m3 cancer without lymph vessel invasion. Use of additional therapy, such as radiotherapy, allows the use of EMR for m3 cancer with lymph vessel invasion or sm1 cancers.

摘要

食管表浅癌可通过手术或内镜安全切除。我们基于临床和病理分析评估了内镜黏膜切除术(EMR)的适应证以及食管表浅癌的最佳治疗方式。在1984年1月1日至1999年9月30日期间,113例食管表浅癌患者接受了手术或内镜切除(n = 33例患者,36个病变)。采用了双通道法、食管EMR管法或带EMR帽的全景内镜。根据日本食管疾病学会的标准,黏膜癌和黏膜下癌被分类为上皮层(m1)、固有黏膜层(m2)、黏膜肌层(m3)、黏膜下层上三分之一(sm1)、黏膜层中三分之一(sm2)或黏膜下层下三分之一(sm3)癌。EMR的绝对适应证限于m1或m2癌,EMR的相对适应证包括m3或sm1病变。在我们科室,EMR的适应证与病变大小或周长无关。浸润黏膜肌层(m3)的病变中淋巴管侵犯和淋巴结转移明显增加。所有采用EMR切除的病变均为0-II(平坦型),10个0-IIa或0-IIb病变的浸润深度为m1或m2。21个0-IIc病变从m1广泛分布至sm1。所有0-IIa + IIc病变均为m3或sm1。61%的患者术前准确建立了诊断。21%的患者检测到与EMR相关的并发症,包括穿孔、狭窄和出血。10例患者在使用EMR后还接受了放疗、化疗或食管切除术加淋巴结清扫。6例m3病变但无淋巴管侵犯的患者未进行此类联合治疗。所有接受EMR治疗的患者,包括未接受额外治疗的m3癌患者,均无复发存活。采用EMR的局部切除可被视为局限于固有黏膜层的食管表浅癌的首选治疗方法。内镜黏膜切除术也可被视为无淋巴管侵犯的m3癌的首选治疗方法。使用放疗等额外治疗可使EMR用于有淋巴管侵犯的m3癌或sm1癌。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验